vs
NBT BANCORP INC（NBTB）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是NBT BANCORP INC的1.1倍（$207.3M vs $184.5M），NBT BANCORP INC净利率更高（27.7% vs -62.0%，领先89.7%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 14.6%）
NBT银行是美国的金融机构，旗下设有176个营业网点，分布于纽约、宾夕法尼亚、佛蒙特、马萨诸塞、新罕布什尔、缅因及康涅狄格州。其母公司为NBT Bancorp Inc.，总部位于美国纽约州诺威奇，在纳斯达克全球精选市场上市，股票代码为NBTB。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
NBTB vs RARE — 直观对比
营收规模更大
RARE
是对方的1.1倍
$184.5M
净利率更高
NBTB
高出89.7%
-62.0%
两年增速更快
RARE
近两年复合增速
14.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $184.5M | $207.3M |
| 净利润 | $51.1M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 27.7% | -62.0% |
| 营收同比 | — | 25.9% |
| 净利润同比 | 127.2% | 3.5% |
| 每股收益（稀释后） | $0.98 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NBTBRARE
| Q1 26 | $184.5M | — | ||
| Q4 25 | $185.1M | $207.3M | ||
| Q3 25 | $186.1M | $159.9M | ||
| Q2 25 | $171.2M | $166.5M | ||
| Q1 25 | $154.7M | $139.3M | ||
| Q4 24 | $148.5M | $164.6M | ||
| Q3 24 | $147.4M | $139.5M | ||
| Q2 24 | $140.4M | $147.0M |
净利润NBTBRARE
| Q1 26 | $51.1M | — | ||
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $54.5M | $-180.4M | ||
| Q2 25 | $22.5M | $-115.0M | ||
| Q1 25 | $36.7M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $38.1M | $-133.5M | ||
| Q2 24 | $32.7M | $-131.6M |
营业利润率NBTBRARE
| Q1 26 | — | — | ||
| Q4 25 | 37.6% | -54.7% | ||
| Q3 25 | 38.6% | -106.9% | ||
| Q2 25 | 17.9% | -64.8% | ||
| Q1 25 | 30.5% | -102.6% | ||
| Q4 24 | 30.7% | -74.3% | ||
| Q3 24 | 33.1% | -94.6% | ||
| Q2 24 | 29.9% | -79.1% |
净利率NBTBRARE
| Q1 26 | 27.7% | — | ||
| Q4 25 | — | -62.0% | ||
| Q3 25 | 29.3% | -112.8% | ||
| Q2 25 | 13.2% | -69.0% | ||
| Q1 25 | 23.8% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | 25.8% | -95.7% | ||
| Q2 24 | 23.3% | -89.5% |
每股收益（稀释后）NBTBRARE
| Q1 26 | $0.98 | — | ||
| Q4 25 | $1.09 | $-1.28 | ||
| Q3 25 | $1.03 | $-1.81 | ||
| Q2 25 | $0.44 | $-1.17 | ||
| Q1 25 | $0.77 | $-1.57 | ||
| Q4 24 | $0.77 | $-1.34 | ||
| Q3 24 | $0.80 | $-1.40 | ||
| Q2 24 | $0.69 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | $160.9M | — |
| 股东权益账面价值 | $1.9B | $-80.0M |
| 总资产 | $16.2B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.08× | — |
8季度趋势，按日历期对齐
现金及短期投资NBTBRARE
| Q1 26 | — | — | ||
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M |
总债务NBTBRARE
| Q1 26 | $160.9M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益NBTBRARE
| Q1 26 | $1.9B | — | ||
| Q4 25 | $1.9B | $-80.0M | ||
| Q3 25 | $1.9B | $9.2M | ||
| Q2 25 | $1.8B | $151.3M | ||
| Q1 25 | $1.6B | $144.2M | ||
| Q4 24 | $1.5B | $255.0M | ||
| Q3 24 | $1.5B | $346.8M | ||
| Q2 24 | $1.5B | $432.4M |
总资产NBTBRARE
| Q1 26 | $16.2B | — | ||
| Q4 25 | $16.0B | $1.5B | ||
| Q3 25 | $16.1B | $1.2B | ||
| Q2 25 | $16.0B | $1.3B | ||
| Q1 25 | $13.9B | $1.3B | ||
| Q4 24 | $13.8B | $1.5B | ||
| Q3 24 | $13.8B | $1.5B | ||
| Q2 24 | $13.5B | $1.6B |
负债/权益比NBTBRARE
| Q1 26 | 0.08× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流NBTBRARE
| Q1 26 | — | — | ||
| Q4 25 | $235.2M | $-99.8M | ||
| Q3 25 | $80.6M | $-91.4M | ||
| Q2 25 | $46.5M | $-108.3M | ||
| Q1 25 | $42.0M | $-166.5M | ||
| Q4 24 | $188.6M | $-79.3M | ||
| Q3 24 | $52.1M | $-67.0M | ||
| Q2 24 | $50.5M | $-77.0M |
自由现金流NBTBRARE
| Q1 26 | — | — | ||
| Q4 25 | $218.9M | $-100.8M | ||
| Q3 25 | $74.3M | $-92.7M | ||
| Q2 25 | $44.1M | $-110.7M | ||
| Q1 25 | $38.3M | $-167.8M | ||
| Q4 24 | $176.8M | $-79.5M | ||
| Q3 24 | $47.8M | $-68.6M | ||
| Q2 24 | $49.1M | $-79.0M |
自由现金流率NBTBRARE
| Q1 26 | — | — | ||
| Q4 25 | 118.2% | -48.6% | ||
| Q3 25 | 40.0% | -58.0% | ||
| Q2 25 | 25.8% | -66.5% | ||
| Q1 25 | 24.8% | -120.5% | ||
| Q4 24 | 119.0% | -48.3% | ||
| Q3 24 | 32.4% | -49.2% | ||
| Q2 24 | 35.0% | -53.7% |
资本支出强度NBTBRARE
| Q1 26 | — | — | ||
| Q4 25 | 8.8% | 0.5% | ||
| Q3 25 | 3.4% | 0.8% | ||
| Q2 25 | 1.4% | 1.5% | ||
| Q1 25 | 2.4% | 1.0% | ||
| Q4 24 | 7.9% | 0.1% | ||
| Q3 24 | 2.9% | 1.2% | ||
| Q2 24 | 1.0% | 1.4% |
现金转化率NBTBRARE
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.48× | — | ||
| Q2 25 | 2.06× | — | ||
| Q1 25 | 1.14× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.37× | — | ||
| Q2 24 | 1.54× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NBTB
| Net Interest Income | $134.3M | 73% |
| Noninterest Income | $50.1M | 27% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
